EE359 Cost-Utility of Bictegravir/Tenofovir Alafenamide/Emtricitabine in Naive Patients over 18 Years of Age Living with Human Immunodeficiency Virus Type 1 Infection, from the Colombian’s Health System Perspective
Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.660
https://www.valueinhealthjournal.com/article/S1098-3015(23)00760-X/fulltext
Title :
EE359 Cost-Utility of Bictegravir/Tenofovir Alafenamide/Emtricitabine in Naive Patients over 18 Years of Age Living with Human Immunodeficiency Virus Type 1 Infection, from the Colombian’s Health System Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)00760-X&doi=10.1016/j.jval.2023.03.660
First page :
Section Title :
Open access? :
No
Section Order :
10140